Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents

European Journal of Medicinal Chemistry

Volumn 62, Issue , 2013, Pages 614-631

  El Nassan, Hala Bakr ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Antimitotic agents; Eg5; Inhibitors; KSP

Indexed keywords

3 HYDROXYPHENYL GROUP; 3,4 METHYLENEDIOXY DERIVATIVE; 4 PIPERIDINYL DERIVATIVE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ARRY 520; AZD 4877; BIPHENYL DERIVATIVE; CAPECITABINE; CARBAZOLE DERIVATIVE; CARBOLINE DERIVATIVE; CPUYL064; CYSTEAMINE DERIVATIVE; DIMETHYLENASTRON; DOCETAXEL; DOXORUBICIN; EMD 534085; ENASTRON; FLUORASTROL; HARMINE; ISPINESIB; IXABEPILONE; LAPATINIB; METHOXYPHENYL DERIVATIVE; MK 0731; MON 97; MONASTROL; PACLITAXEL; PHENYL GROUP; THIADIAZOLE DERIVATIVE; TRASTUZUMAB; TRIFLUOROMETHYL DERIVATIVE; TRITYL LEVO CYSTEINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

BINDING SITE; BLADDER CANCER; BREAST CANCER; HUMAN; LUNG CANCER; MITOSIS INHIBITION; OVARY CANCER; PANCREAS CANCER; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG DISCOVERY; HUMANS; KINESIN; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874168580     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.01.031     Document Type: Review

References (167)

1. L. Wordeman Cytoskeleton and human disease M. Kavallaris, Chapter 3: The Kinesin Superfamily 2012
2. N. Hirokawa Kinesin and dynein superfamily proteins and the mechanism of organelle transport Science 279 1998 519 526
3. S.A. Endow Microtubule motors in spindle and chromosome motility Eur. J. Biochem. 262 1999 12 18
4. E. Mandelkow, and E.M. Mandelkow Kinesin motors and disease Trends Cell. Biol. 12 2002 585 591
5. R.D. Vale, and R.A. Milligan The way things move: looking under the hood of molecular motor proteins Science 288 2000 88 95
6. V. Sarli, and A. Giannis Targeting the kinesin spindle protein: basic principles and clinical implications Clin. Cancer Res. 14 2008 7583 7587
7. K.W. Wood, and G. Bergnes Mitotic kinesin inhibitors as novel anticancer agents Annu. Rep. Med. Chem. 39 2004 173 183
8. A. Blangy, H.A. Lane, P. d'Herin, M. Harper, M. Kress, and E.A. Nigg Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo Cell 83 1995 1159 1169
9. H.V. Goodson, S.J. Kang, and S.A. Endow Molecular phylogeny of the kinesin family of microtubule motor proteins J. Cell Sci. 107 1994 1875 1884
10. C.E. Walczak, and T.J. Mitchison Kinesin-related proteins at mitotic spindle poles: function and regulation Cell 85 1996 943 946
11. C.J. Lawrence, R.K. Dawe, K.R. Christie, D.W. Cleveland, S.C. Dawson, S.A. Endow, L.S. Goldstein, H.V. Goodson, N. Hirokawa, J. Howard, R.L. Malmberg, J.R. McIntosh, H. Miki, T.J. Mitchison, Y. Okada, A.S. Reddy, W.M. Saxton, M. Schliwa, J.M. Scholey, R.D. Vale, C.E. Walczak, and L. Wordeman A standardized kinesin nomenclature J. Cell Biol. 167 2004 19 22
12. V. Mountain, C. Simerly, L. Howard, A. Ando, G. Schatten, and D.A. Compton The kinesin-related protein, HSET, opposes the activity of Eg5 and crosslinks microtubules in the mammalian mitotic spindle J. Cell Biol. 147 1999 351 366
13. J.G. DeLuca, C.N. Newton, R.H. Himes, M.A. Jordan, and L. Wilson Purification and characterization of native conventional kinesin, HSET, and CENP-E from mitotic HeLa cells J. Biol. Chem. 276 2002 28014 28021
14. A. Blangy, L. Arnaud, and E.A. Nigg Phosphorylation by p34cdc2 protein kinase regulates binding of the kinesin-related motor HsEg5 to the dynactin subunit p150 J. Biol. Chem. 272 1997 19418 19424
15. S. DeBonis, J.P. Simorre, I. Crevel, L. Lebeau, D.A. Skoufias, A. Blangy, C. Ebel, P. Gans, R. Cross, D.D. Hackney, R.H. Wade, and F. Kozielski Interaction of the mitotic inhibitor monastrol with human kinesin Eg5 Biochemistry 42 2003 338 349
16. S. Inoue, and E.D. Salmon Force generation by microtubule assembly/disassembly in mitosis and related movements Mol. Biol. Cell 6 1995 1619 1640
17. D.A. Compton Spindle assembly in animal cells Annu. Rev. Biochem. 69 2000 95 114
18. L. Ferhat, C. Cook, M. Chauviere, C. Muriel, M. Harper, M. Kress, G.E. Lyons, and P.W. Baas Expression of the mitotic motor protein Eg5 in postmitotic neurons: implications for neuronal development J. Neurosci. 18 1998 7822 7835
19. P.S. Hegde, J. Cogswell, K. Carrick, J. Jackson, K.W. Wood, W.K. Eng, M. Brawner, P.S. Huang, and D. Bergsma Differential gene expression analysis of kinesin spindle protein in human solid tumors Proc. Am. Soc. Clin. Oncol. 22 2003 Abstract 535
20. B.Z. Carter, D.H. Mak, Y. Shi, W.D. Schoeber, R.Y. Wang, M. Konopleva, E. Koller, N.M. Dean, and M. Andreeff Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance Cell Cycle 5 2006 2223 2229
21. G.M. Hansen, and M.J. Justice Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia Oncogene 18 1999 6531 6539
22. S. Ding, N. Xing, J. Lu, H. Zhang, K. Nishizawa, S. Liu, X. Yuan, Y. Qin, Y. Liu, O. Ogawa, and H. Nishiyama Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma Int. J. Urol. 18 2011 432 438
23. M. Liu, X. Wang, Y. Yang, D. Li, H. Ren, Q. Zhu, Q. Chen, S. Han, J. Hao, and J. Zhou Ectopic expression of the microtubule-dependent motor protein Eg5 promotes pancreatic tumourigenesis J. Pathol. 221 2010 221 228
24. A. Castillo, H.C. Morse 3rd, V.L. Godfrey, R. Naeem, and M.J. Justice Overexpression of Eg5 causes genomic instability and tumor formation in mice Cancer Res. 67 2007 10138 10147
25. A. Masuda, K. Maeno, T. Nakagawa, H. Saito, and T. Takahashi Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers Am. J. Pathol. 163 2003 1109 1116
26. V. Sarli, and A. Giannis Inhibitors of mitotic kinesins: next-generation antimitotics ChemMedChem 1 2006 293 298
27. N. Hayashi, E. Koller, L. Fazli, and M.E. Gleave Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity Prostate 68 2008 1283 1295
28. M. Liu, H. Yu, L. Huo, J. Liu, M. Li, and J. Zhou Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor Biochem. Pharmacol. 76 2008 169 178
29. R. Nakai, S. Iida, T. Takahashi, T. Tsujita, S. Okamoto, C. Takada, K. Akasaka, S. Ichikawa, H. Ishida, H. Kusaka, S. Akinaga, C. Murakata, S. Honda, M. Nitta, H. Saya, and Y. Yamashita K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells Cancer Res. 69 2009 3901 3909
30. G.A. Orr, P. Verdier-Pinard, H. McDaid, and S.B. Horwitz Mechanisms of taxol resistance related to microtubules Oncogene 22 2003 7280 7295
31. H.C. Joshi Microtubule dynamics in living cells Curr. Opin. Cell. Biol. 10 1998 35 44
32. J. Lane, and V. Allan Microtubule-based membrane movement Biochim. Biophys. Acta 1376 1998 27 55
33. A. Desai, and T.J. Mitchison Microtubule polymerization dynamics Annu. Rev. Cell. Dev. Biol. 13 1997 83 117
34. R. Sakowicz, J.T. Finer, C. Beraud, A. Crompton, E. Lewis, A. Fritsch, Y. Lee, J. Mak, R. Moody, R. Turincio, J.C. Chabala, P. Gonzales, S. Roth, S. Weitman, and K.W. Wood Antitumor activity of a kinesin inhibitor Cancer Res. 64 2004 3276 3280
35. J.R. Jackson, D.R. Patrick, M.M. Dar, and P.S. Huang Targeted anti-mitotic therapies: can we improve on tubulin agents ? Nat. Rev. Cancer 7 2007 107 117
36. A.I. Marcus, U. Peters, S.L. Thomas, S. Garrett, A. Zelnak, T.M. Kapoor, and P. Giannakakou Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells J. Biol. Chem. 280 2005 11569 11577
37. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
38. J. Turner, R. Anderson, J. Guo, C. Beraud, R. Fletterick, and R. Sakowicz Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker J. Biol. Chem. 276 2001 25496 25502
39. C. Jiang, Q. You, Z. Li, and Q. Guo Kinesin spindle protein inhibitors as anticancer agents Expert Opin. Ther. Patents 16 2006 1517 1532
40. K. Matsuno, J. Sawada, and A. Asai Therapeutic potential of mitotic kinesin inhibitors in cancer Expert Opin. Ther. Patents 18 2008 253 274
41. Y. Zhang, and W. Xu Progress on kinesin spindle protein inhibitors as anti-cancer agents Anticancer Agents Med. Chem. 8 2008 698 704
42. S.D. Knigh, and C.A. Parrish Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP Curr. Top. Med. Chem. 8 2008 888 904
43. D. Huszar, M. Theoclitou, J. Skolnik, and R. Herbst Kinesin motor proteins as targets for cancer therapy Cancer Metastasis Rev. 28 2009 197 208
44. T.U. Mayer, T.M. Kapoor, S.J. Haggarty, R.W. King, S.L. Schreiber, and T.J. Mitchison Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 286 1999 971 974
45. Z. Maliga, T.M. Kapoor, and T.J. Mitchison Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 Chem. Biol. 9 2002 989 996
46. C.O. Kappe Biologically active dihydropyrimidones of the Biginelli-type-a literature survey Eur. J. Med. Chem. 35 2000 1043 1052
47. D. Dallinger, and C.O. Kappe Rapid preparation of the mitotic kinesin Eg5 inhibitor monastrol using controlled microwave-assisted synthesis Nat. Protoc. 2 2007 317 321
48. T.N. Glasnov, H. Tye, and C.O. Kappe Integration of high speed microwave chemistry and a statistical 'design of experiment' approach for the synthesis of the mitotic kinesin Eg5 inhibitor monastrol Tetrahedron 64 2008 2035 2041
49. C.O. Kappe, O.V. Shishkin, G. Uray, and P. Verdino X-ray structure, conformational analysis, enantioseparation, and determination of absolute configuration of the mitotic kinesin Eg5 inhibitor monastrol Tetrahedron 56 2000 1859 1862
50. M.A. Blasco, S. Thumann, J. Wittmann, A. Giannis, and H. Groger Enantioselective biocatalytic synthesis of (S)-monastrol Bioorg. Med. Chem. Lett. 20 2010 4679 4682
51. A. Dondoni, A. Massi, and S. Sabbatini Improved synthesis and preparative scale resolution of racemic monastrol Tetrahedron Lett. 43 2002 5913 5916
52. Y. Huang, F. Yang, and C. Zhu Highly enantioseletive Biginelli reaction using a new chiral ytterbium catalyst: asymmetric synthesis of dihydropyrimidines J. Am. Chem. Soc. 127 2005 16386 16387
53. Z. Maliga, and T.J. Mitchison Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol BMC Chem. Biol. 6 2006 2 9
54. Z. Maliga, J. Xing, H. Cheung, L.J. Juszczak, J.M. Friedman, and S.S. Rosenfeld A pathway of structural changes produced by monastrol binding to Eg5 J. Biol. Chem. 281 2006 7977 7982
55. D. Russowsky, R.F.S. Canto, S.A.A. Sanches, M.G.M. D'Oca, A. Fatima, R.A. Pilli, L.K. Kohn, M.A. Antonio, and J.E. Carvalho Synthesis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: monastrol, oxo-monastrol and oxygenated analogues Bioorg. Chem. 34 2006 173 182
56. I. Garcia-Saez, S. DeBonis, R. Lopez, F. Trucco, B. Rousseau, P. Thuery, and F. Kozielsk Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration J. Biol. Chem. 282 2007 9740 9747
57. M. Gartner, N. Sunder-Plassmann, J. Seiler, M. Utz, I. Vernos, T. Surrey, and A. Giannis Development and biological evaluation of potent and specific inhibitors of mitotic kinesin Eg5 ChemBioChem 6 2005 1173 1177
58. H.Y.K. Kaan, V. Ulaganathan, O. Rath, H. Prokopcova, D. Dallinger, C.O. Kappe, and F. Kozielski Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol J. Med. Chem. 53 2010 5676 5683
59. L. Yang, C. Jiang, F. Liu, Q. You, and W. Wu Cloning, enzyme characterization of recombinant human Eg5 and the development of a new Inhibitor Biol. Pharm. Bull. 31 2008 1397 1402
60. J. Svetlik, L. Veizerov, T.U. Mayer, and M. Catarinella Monastrol analogs: a synthesis of pyrazolopyridine, benzopyranopyrazolopyridine, and oxygen-bridged azolopyrimidine derivatives and their biological screening Bioorg. Med. Chem. Lett. 20 2010 4073 4076
61. E. Klein, S. DeBonis, B. Thiede, D.A. Skoufias, F. Kozielski, and L. Lebeau New chemical tools for investigating human mitotic kinesin Eg5 Bioorg. Med. Chem. 15 2007 6474 6488
62. H. Prokopcov, D. Dallinger, G. Uray, H.Y.K. Kaan, V. Ulaganathan, F. Kozielski, C. Laggner, and C.O. Kappe Structure-activity relationships and molecular docking of novel dihydropyrimidine-based mitotic Eg5 inhibitors ChemMedChem 5 2010 1760 1769
63. S.A. Haque, T.P. Hasaka, A.D. Brooks, P.V. Lobanov, and P.W. Baas Monastrol, a prototype anti-cancer drug that inhibits a mitotic kinesin, induces rapid bursts of axonal outgrowth from cultured postmitotic neurons Cell. Motil. Cytoskeleton 58 2004 10 16
64. Y. Chen, J.P.H. Chow, and R.Y.C. Poon Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe Mol. Cancer Res. 10 2012 626 635
65. K.Y. Zee-Cheng, and C.C. Cheng Experimental antileukemic agents. Preparation and structure-activity study of S-tritylcysteine and related compounds J. Med. Chem. 13 1970 414 418
66. D. Kessel, G. Smith, and J. Blahnik Effects of S-(trityl)-l-cysteine and its analogs on cell surface properties of leukemia L1210 cells Biochem. Pharmacol. 25 1976 1893 1897
67. K.D. Paull, C.M. Lin, L. Malspeis, and E. Hamel Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data Cancer Res. 52 1992 3892 3900
68. M.R. Boyd, and K.D. Paull Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen Drug Dev. Res. 34 1995 91 109
69. S. DeBonis, D.A. Skoufias, L. Lebeau, R. Lopez, G. Robin, R.L. Margolis, R.H. Wade, and F. Kozielski In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities Mol. Cancer Ther. 3 2004 1079 1090
70. D.A. Skoufias, S. DeBonis, Y. Saoudi, L. Lebeau, I. Crevel, R. Cross, R.H. Wade, D. Hackney, and F. Kozielski S-Trityl-l-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression J. Biol. Chem. 281 2006 17559 17569
71. S. Brier, D. Lemaire, S. Debonis, E. Forest, and F. Kozielski Identification of the protein binding region of S-trityl-l-cysteine, a new potent inhibitor of the mitotic kinesin Eg5 Biochemistry 43 2004 13072 13082
72. S. DeBonis, D.A. Skoufias, R. Indorato, F. Liger, B. Marquet, C. Laggner, B. Joseph, and F. Kozielski Structure-activity relationship of S-trityl-l-cysteine analogues as inhibitors of the human mitotic kinesin Eg5 J. Med. Chem. 51 2008 1115 1125
73. C. Wiltshire, B.L. Singh, J. Stockley, J. Fleming, B. Doyle, R. Barnetson, C.N. Robson, F. Kozielski, and H.Y. Leung Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-l-cysteine-mediated Eg5 inhibition Mol. Cancer Ther. 9 2010 1730 1739
74. N. Ogo, S. Oishi, K. Matsuno, J. Sawada, N. Fujii, and A. Asai Synthesis and biological evaluation of l-cysteine derivatives as mitotic kinesin Eg5 inhibitors Bioorg. Med. Chem. Lett. 17 2007 3921 3924
75. M. Shimizu, H. Ishii, N. Ogo, Y. Unno, K. Matsuno, J. Sawada, Y. Akiyama, and A. Asai S-Trityl-l-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line Cancer Lett. 298 2010 99 106
76. H.Y. Kaan, J. Weiss, D. Menger, V. Ulaganathan, K. Tkocz, C. Laggner, F. Popowycz, B. Joseph, and F. Kozielski Structure-activity relationship and multidrug resistance study of new S-trityl-l-cysteine derivatives as inhibitors of Eg5 J. Med. Chem. 54 2011 1576 1586
77. S. Ding, K. Nishizawa, T. Kobayashi, S. Oishi, J. Lv, N. Fujii, O. Ogawa, and H. Nishiyama A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-l-cysteine, a novel Eg5 inhibitor J. Urol. 184 2010 1175 1181
78. N.D. Xing, S.T. Ding, R. Saito, K. Nishizawa, T. Kobayashi, T. Inoue, S. Oishi, N. Fujii, J.J. Lv, O. Ogawa, and H. Nishiyama A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-l-cysteine, a novel Eg5 inhibitor Asian J. Androl. 13 2011 236 241
79. M. Shimizu, H. Ishii, N. Ogo, K. Matsuno, and A. Asai Biochemical analysis of cellular target of S-trityl-l-cysteine derivatives using affinity matrix Bioorg. Med. Chem. Lett. 20 2010 1578 1580
80. D. Rodriguez, C. Ramesh, L.H. Henson, L. Wilmeth, B.K. Bryant, S. Kadavakollu, R. Hirsch, J. Montoya, P.R. Howell, J.M. George, D. Alexander, D.L. Johnson, J.B. Arterburn, and C.B. Shuster Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity Bioorg. Med. Chem. 19 2011 5446 5453
81. F. Wang, J.A.D. Good, O. Rath, H.Y.K. Kaan, O.B. Sutcliffe, S.P. Mackay, and F. Kozielski Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity J. Med. Chem. 55 2012 1511 1525
82. H.Y.K. Kaan, V. Ulaganathan, D.D. Hackney, and F. Kozielski An allosteric transition trapped in an intermediate state of a new kinesin inhibitor complex Biochem. J. 425 2009 55 60
83. M.N. Abualhasan, J.A.D. Good, K. Wittayanarakul, N.G. Anthony, G. Berretta, O. Rath, F. Kozielski, O.B. Sutcliffe, and S.P. Mackay Doing the methylene shuffle further insights into the inhibition of mitotic kinesin Eg5 with S-trityl l-cysteine Eur. J. Med. Chem. 54 2012 483 498
84. S. Tcherniuk, R. van Lis, F. Kozielski, and D.A. Skoufias Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-l-cysteine in tumor derived cell lines Biochem. Pharmacol. 79 2010 864 872
85. S. Brier, D. Lemaire, S. DeBonis, E. Forest, and F. Kozielski Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents J. Mol. Biol. 360 2006 360 376
86. S. Hotha, J.C. Yarrow, J.G. Yang, S. Garrett, K.V. Renduchintala, T.U. Mayer, and T.M. Kapoor HR22C16: a potent small-molecule probe for the dynamics of cell division Angew. Chem. Int. Ed. 42 2003 2379 2382
87. S. Xiao, and X. Shi The first highly stereoselective approach to the mitotic kinesin Eg5 inhibitor HR22C16 and its analogues Tetrahedron: Asymmetry 21 2010 226 231
88. N. Sunder-Plassmann, V. Sarli, M. Gartner, M. Utz, J. Seiler, S. Huemmer, T.U. Mayer, T. Surrey, and A. Giannis Synthesis and biological evaluation of new tetrahydro-β-carbolines as inhibitors of the mitotic kinesin Eg5 Bioorg. Med. Chem. 13 2005 6094 6111
89. P.A. Barsanti, W. Wang, Z. Ni, D. Duhl, N. Brammeier, E. Martin, D. Bussiere, and A.O. Walter The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5 Bioorg. Med. Chem. Lett. 20 2010 157 160
90. S.F. Liu, L. Yu, C. Jiang, L. Yang, W. Wu, and Q. You Discovery of tetrahydro-β-carbolines as inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. 18 2010 4167 4177
91. S. Oishi, T. Watanabe, J. Sawada, A. Asai, H. Ohno, and N. Fujii Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds J. Med. Chem. 53 2010 5054 5058
92. T. Takeuchi, S. Oishi, T. Watanabe, H. Ohno, J. Sawada, K. Matsuno, A. Asai, N. Asada, K. Kitaura, and N. Fujii Structure activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors J. Med. Chem. 54 2011 4839 4846
93. R.K. Johnson, F.L. McCabe, E. Cauder, L. Inlow-Porter, M. Whitacre, J.D. Winkler, G. Bergnes, B. Feng, D. Morgans, K.W. Wood, and J.R. Jackson SB-715992, a potent and selective inhibitor of KSP mitotic kinesin, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts Proc. Annu. Meet. Am. Assoc. Cancer Res. 43 2002 269
94. L. Lad, L. Luo, J.D. Carson, K.W. Wood, J.J. Hartman, R.A. Copeland, and R. Sakowicz Mechanism of inhibition of human KSP by ispinesib Biochemistry 47 2008 3576 3585
95. B. Zhang, J. Liu, Y. Xu, and S. Ng Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity Biochem. Biophys. Res. Commun. 372 2008 565 570
96. D.A. Davis, S.H. Sarkar, M. Hussain, Y. Li, and F.H. Sarkar Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line BMC Cancer 6 2006 22 30
97. S.P. Blagden, L.R. Molife, A. Seebaran, M. Payne, A.H.M. Reid, A.S. Protheroe, L.S. Vasist, D.D. Williams, C. Bowen, S.J. Kathman, J.P. Hodge, M.M. Dar, J.S. de Bono, and M.R. Middleton A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours Br. J. Cancer 98 2008 894 899
98. P.A. Tang, L.L. Siu, E.X. Chen, S.J. Hotte, S. Chia, J.K. Schwarz, G.R. Pond, C. Johnson, A.D. Colevas, T.W. Synold, L.S. Vasist, and E. Winquist Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck Invest. New Drugs 26 2008 257 264
99. J.J. Knox, S. Gill, T.W. Synold, J.J. Biagi, P. Major, R. Feld, C. Cripps, N. Wainman, E. Eisenhauer, and L. Seymour A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168) Invest. New Drugs 26 2008 265 272
100. R.T. Lee, K.E. Beekman, M. Hussain, N.B. Davis, J.I. Clark, S.P. Thomas, K.F. Nichols, and W.M. Stadler A university of chicago consortium phase II trial of SB-715992 in advanced renal cell cancer Clin. Genitourin. Cancer 6 2008 21 24
101. T.M. Beer, B. Goldman, T.W. Synold, C.W. Ryan, L.S. Vasist, P.J. Van Veldhuizen, S.R. Dakhil, P.N. Lara, A. Drelichman, M.H.A. Hussain, and E.D. Crawford Southwest oncology group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes Clin. Genitourin. Cancer 6 2008 103 109
102. C.W. Lee, K. Bélanger, S.C. Rao, T.M. Petrella, R.G. Tozer, L. Wood, K.J. Savage, E.A. Eisenhauer, T.W. Synold, N. Wainman, and L. Seymour A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial Invest. New Drugs 26 2008 249 255
103. H. Carol, R. Lock, P.J. Houghton, C.L. Morton, E.A. Kolb, R. Gorlick, C.P. Reynolds, J.M. Maris, S.T. Keir, C.A. Billups, and M.A. Smith Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program Pediatr. Blood Cancer 53 2009 1255 1263
104. A. Souid, R.L. Dubowy, A.M. Ingle, M.G. Conlan, J. Sun, S.M. Blaney, and P.C. Adamson A pediatric phase 1 trial and pharmacokinetic study of ispinesib: a children's oncology group phase I consortium study Pediatr. Blood Cancer 55 2010 1323 1328
105. J.W. Purcell, J. Davis, M. Reddy, S. Martin, K. Samayoa, H. Vo, K. Thomsen, P. Bean, W.L. Kuo, S. Ziyad, J. Billig, H.S. Feiler, J.W. Gray, K.W. Wood, and S. Cases Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast Cancer Clin. Cancer Res. 16 2010 566 576
106. H.L. Gomez, M. Philco, P. Pimentel, M. Kiyan, M.L. Monsalvo, M.G. Conlan, K.G. Saikali, M.M. Chen, J.J. Seroogy, A.A. Wolff, and R.D. Escandon Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer Anti-cancer Drugs 23 2012 335 341
107. H.A. Burris III, S.F. Jones, D.D. Williams, S.J. Kathman, J.P. Hodge, L. Pandite, P.T.C. Ho, S.A. Boerner, and P. LoRusso A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors Invest. New Drugs 29 2011 467 472
108. J.R. Jackson, A. Gilmartin, D. Dhanak, A. Gilmartin, D. Dhanak, S. Knight, C. Parrish, L. Luo, D. Sutton, E. Caulder, M. Diamond, M. Giardiniere, S.Y. Zhang, P. Huang, G. Bergnes, A. McDonald, Y. Lee, R. Sakowicz, and K.W. Wood A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer Proc. Am. Assoc. Cancer Res. 2006 B1
109. K.D. Holen, C.P. Belani, G. Wilding, S. Ramalingam, J.L. Volkman, R.K. Ramanathan, L.S. Vasist, C.J. Bowen, J.P. Hodge, M.M. Dar, and P.T.C. Ho A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose Cancer Chemother. Pharmacol. 67 2011 447 454
110. C. Jiang, L. Yang, W.T. Wu, Q.L. Guo, and Q.D. You De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors Bioorg. Med. Chem. 19 2011 5612 5627
111. M.E. Theoclitou, B. Aquila, M.H. Block, P.J. Brassil, L. Castriotta, E. Code, M.P. Collins, A.M. Davies, T. Deegan, J. Ezhuthachan, S. Filla, E. Freed, H. Hu, D. Huszar, M. Jayaraman, D. Lawson, P.M. Lewis, M.V.P. Nadella, V. Oza, M. Padmanilayam, T. Pontz, L. Ronco, D. Russell, D. Whitston, and X. Zheng Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2] thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent J. Med. Chem. 54 2011 6734 6750
112. L. Marquis, M. Tran, W. Choi, I.L. Lee, D. Huszar, A. Siefker, C. Dinney, and D.J. McConkey p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells Cancer Biol. Ther. 13 2012 477 486
113. T. Esaki, T. Seto, H. Ariyama, S. Arita, C. Fujimoto, K. Tsukasa, T. Kometani, K. Nosaki, F. Hirai, and K. Yagawa Phase I study to assess the safety, tolerability and pharmacokinetics of AZD4877 in Japanese patients with solid tumors Arch. Drug Inf. 4 2011 23 31
114. J.R. Infante, J.L. Spratlin, R. Kurzrock, S.G. Eckhardt, H.A. Burris, T.A. Pulchalski, J. Li, K. Wu, J. Ochs, and R.S. Herbst Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors J. Clin. Oncol. 26 15S 2008 Abstract 2501
115. H.M. Kantarjian, S. Padmanabhan, W. Stock, M.S. Tallman, G.A. Curt, J. Li, A. Osmukhina, K. Wu, D. Huszar, G. Borthukar, S. Faderl, G. Garcia-Manero, T. Kadia, K. Sankhala, O. Odenike, J.K. Altman, and M. Minden Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia Invest. New Drugs 30 2012 1107 1115
116. J.R. Infante, R. Kurzrock, J. Spratlin, H.A. Burris, S.G. Eckhardt, J. Li, K. Wu, J.M. Skolnik, L. Hylander-Gans, A. Osmukhina, D. Huszar, and R.S. Herbst A phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors Cancer Chemother. Pharmacol. 69 2012 165 172
117. J.F. Gerecitano, J.J. Stephenson, N.L. Lewis, A. Osmukhina, J. Li, K. Wu, Z. You, D. Huszar, J.M. Skolnik, G.K. Schwartz, Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest. New Drugs, in press.
118. K. Schiemann, D. Finsinger, F. Zenke, C. Amendt, T. Knochel, D. Bruge, H. Buchstaller, U. Emde, W. Stahle, and S. Anzali The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolones (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 Bioorg. Med. Chem. Lett. 20 2010 1491 1495
119. J.D. Orth, A. Loewer, G. Lahav, and T.J. Mitchison Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction Mol. Biol. Cell. 23 2012 567 576
120. Y. Tang, J.D. Orth, T. Xie, and T.J. Mitchison Rapid induction of apoptosis during kinesin-5 inhibitor-induced mitosis arrest in HL60 cells Cancer Lett. 310 2011 15 24
121. R. Woessner, B. Tunquist, C. Lemieux, E. Chlipala, S. Jackinsky, W. Dewolf, W. Voegtli, A. Cox, S. Rana, P. Lee, and D. Walker ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models Anticancer Res. 29 2009 4373 4380
122. H.J. Khoury, G. Garcia-Manero, G. Borthakur, T. Kadia, M.C. Foudray, M. Arellano, A. Langston, B. Bethelmie-Bryan, S. Rush, K. Litwiler, S. Karan, H. Simmons, A.I. Marcus, M. Ptaszynski, and H. Kantarjian A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias Cancer 118 2012 3556 3564
123. K.H. Kim, Y. Xie, E.M. Tytler, R. Woessner, G. Mor, and A.B. Alvero KSP inhibitor ARRY-520 as a substitute for paclitaxel in type I ovarian cancer cells J. Trans. Med. 7 2009 63 71
124. B.Z. Carter, D.H. Mak, R. Woessner, S. Gross, W.D. Schober, Z. Estrov, H. Kantarjian, and M. Andreeff Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells Leukemia 23 2009 1755 1762
125. B.J. Tunquist, R.D. Woessner, and D.H. Walker Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520 Mol. Cancer Ther. 9 2010 2046 2056
126. A.D. Basso, M. Liu, C. Dai, K. Gray, L. Nale, S. Tevar, S. Lee, L. Liang, A. Ponery, B. Yaremko, E. Smith, H. Tang, P.R. Sheth, M.A. Siddiqui, D.J. Hicklin, and P. Kirschmeier SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics Mol. Cancer Ther. 9 2010 2993 3002
127. C.D. Cox, M.J. Breslin, B.J. Mariano, P.J. Coleman, C.A. Buser, E.S. Walsh, K. Hamilton, H.E. Huber, N.E. Kohl, M. Torrent, Y. Yan, L.C. Kuo, and G.D. Hartman Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin Bioorg. Med. Chem. Lett. 15 2005 2041 2045
128. C.D. Cox, M. Torrent, M.J. Breslin, B.J. Mariano, D.B. Whitman, P.J. Coleman, C.A. Buser, E.S. Walsh, K. Hamilton, and M.D. Schaber Kinesin spindle protein (KSP) inhibitors. Part 4: structure-based design of 5-alkylamino-3,5- diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 16 2006 3175 3179
129. P.J. Coleman, J.D. Schreier, C.D. Cox, M.E. Fraley, R.M. Garbaccio, C.A. Buser, E.S. Walsh, K. Hamilton, R.B. Lobell, K. Rickert, W. Tao, R.E. Diehl, V.J. South, J.P. Davide, N.E. Kohl, Y. Yan, L. Kuo, T. Prueksaritanont, C. Li, E.A. Mahan, C. Fernandez-Metzler, J.J. Salata, and G.D. Hartman Kinesin spindle protein (KSP) inhibitors. Part 6: design and synthesis of 3,5-diaryl-4,5- dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 17 2007 5390 5395
130. A.J. Roecker, P.J. Coleman, S.P. Mercer, J.D. Schreier, C.A. Buser, E.S. Walsh, K. Hamilton, R.B. Lobell, W. Tao, R.E. Diehl, V.J. South, J.P. Davide, N.E. Kohl, Y. Yan, L. Kuo, C. Li, C. Fernandez-Metzler, E.A. Mahan, T. Prueksaritanont, and G.D. Hartmana Kinesin spindle protein (KSP) inhibitors. Part 8: design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 17 2007 5677 5682
131. M.E. Fraley, R.M. Garbaccio, K.L. Arrington, W.F. Hoffman, E.S. Tasber, P.J. Coleman, C.A. Buser, E.S. Walsh, K. Hamilton, C. Fernandes, M.D. Schaber, R.B. Lobell, W. Tao, V.J. South, Y. Yan, L.C. Kuo, T. Prueksaritanont, C. Shu, M. Torrent, D.C. Heimbrook, N.E. Kohl, H.E. Huberb, and G.D. Hartman Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 16 2006 1775 1779
132. R.M. Garbaccio, M.E. Fraley, E.S. Tasber, C.M. Olson, W.F. Hoffman, K.L. Arrington, M. Torrent, C.A. Buser, E.S. Walsh, K. Hamilton, M.D. Schaber, C. Fernandes, R.B. Lobell, W. Tao, V.J. South, Y. Yan, L.C. Kuo, T. Prueksaritanont, D.E. Slaughter, C. Shu, D.C. Heimbrook, N.E. Kohl, H.E. Huber, and G.D. Hartman Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility Bioorg. Med. Chem. Lett. 16 2006 1780 1783
133. C.D. Cox, M.J. Breslin, D.B. Whitman, P.J. Coleman, R.M. Garbaccio, M.E. Fraley, M.M. Zrada, C.A. Buser, E.S. Walsh, K. Hamilton, R.B. Lobell, W. Tao, M.T. Abrams, V.J. South, H.E. Huber, N.E. Kohl, and G.D. Hartman Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5- dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorg. Med. Chem. Lett. 17 2007 2697 2702
134. C.D. Cox, P.J. Coleman, M.J. Breslin, D.B. Whitman, R.M. Garbaccio, M.E. Fraley, C.A. Buser, E.S. Walsh, K. Hamilton, M.D. Schaber, R.B. Lobell, W. Tao, J.P. Davide, R.E. Diehl, M.T. Abrams, V.J. South, H.E. Huber, M. Torrent, T. Prueksaritanont, C. Li, D.E. Slaughter, E. Mahan, C. Fernandez-Metzler, Y. Yan, L.C. Kuo, N.E. Kohl, and G.D. Hartman Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1- methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H- pyrrole-1-carboxamide (MK-0731) for the treatment of taxane refractory cancer J. Med. Chem. 51 2008 4239 4252
135. K. Holen, R. DiPaola, G. Liu, A.R. Tan, G. Wilding, K. Hsu, N. Agrawal, C. Chen, L. Xue, E. Rosenberg, and M. Stein A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors Invest. New Drugs 30 2012 1088 1095
136. R.M. Garbaccio, E.S. Tasber, L.A. Neilson, P.J. Coleman, M.E. Fraley, C.
137. C.M. Tarby, R.F. Kaltenbach, T. Huynh, A. Pudzianowski, H. Shen, M. Ortega-Nanos, S. Sheriff, J.A. Newitt, P.A. McDonnell, N. Burford, C.R. Fairchild, W. Vaccaro, Z. Chen, R.M. Borzilleri, J. Naglich, L.J. Lombardo, M. Gottardis, G.L. Trainor, and D.L. Roussell Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series Bioorg. Med. Chem. Lett. 16 2006 2095 2100
138. F. Liu, Q.D. You, and Y.D. Chen Pharmacophore identification of KSP inhibitors Bioorg. Med. Chem. Lett. 17 2007 722 726
139. C. Jiang, Q. You, F. Liu, W. Wu, Q. Guo, J. Chern, L. Yang, and M. Chen Design, synthesis and evaluation of tetrahydroisoquinolines as new kinesin spindle protein inhibitors Chem. Pharm. Bull. 57 2009 567 571
140. S. Nagarajan, D.A. Skoufias, F. Kozielski, and A.N. Pae Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors J. Med. Chem. 55 2012 2561 2573
141. C.A. Parrish, N.D. Adams, K.R. Auger, J.L. Burgess, J.D. Carson, A.M. Chaudhari, R.A. Copeland, M.A. Diamond, C.A. Donatelli, K.J. Duffy, L.F. Faucette, J.T. Finer, W.F. Huffman, E.D. Hugger, J.R. Jackson, S.D. Knight, L. Luo, M.L. Moore, K.A. Newlander, L.H. Ridgers, R. Sakowicz, A.N. Shaw, C.M. Sung, D. Sutton, K.W. Wood, S. Zhang, M.N. Zimmerman, and D. Dhanak Novel ATP-competitive kinesin spindle protein inhibitors J. Med. Chem. 50 2007 4939 4952
142. L. Luo, C.A. Parrish, N. Nevins, D.E. McNulty, A.M. Chaudhari, J.D. Carson, V. Sudakin, A.N. Shaw, R. Lehr, H. Zhao, S. Sweitzer, L. Lad, K.W. Wood, R. Sakowicz, R.S. Annan, P.S. Huang, J.R. Jackson, D. Dhanak, R.A. Copeland, and K.R. Auger ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism Nat. Chem. Biol. 33 2007 722 726
143. K. Matsuno, J. Sawada, M. Sugimoto, N. Ogo, and A. Asai Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors Bioorg. Med. Chem. Lett. 19 2009 1058 1061
144. B.R. Lahue, Y. Ma, G.W. Shipps, W. Seghezzi, and R. Herbst Substituted benzimidazoles: a novel chemotype for small molecule hKSP inhibitors Bioorg. Med. Chem. Lett. 19 2009 3405 3409
145. P.R. Sheth, G.W. Shipps, W. Seghezzi, C.K. Smith, C. Chuang, D. Sanden, A.D. Basso, L. Vilenchik, K. Gray, D.A. Annis, E. Nickbarg, Y. Ma, B. Lahue, R. Herbst, and H.V. Le Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain Biochemistry 49 2010 8350 8358
146. C. Jiang, L. Yang, W. Wu, Q. Guo, and Q. You CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity J. Pharm. Pharmacol. 63 2011 1462 1469
147. J. Nakazawa, J. Yajima, T. Usui, M. Ueki, A. Takatsuki, M. Imoto, Y.Y. Toyoshima, and H. Osada A novel action of terpendole E on the motor activity of mitotic kinesin Eg5 Chem. Biol. 10 2003 131 137
148. F. Churruca, M. Fousteris, Y. Ishikawa, M.W. Rekowski, C. Hounsou, T. Surrey, and A. Giannis A novel approach to indoloditerpenes by nazarov photocyclization: synthesis and biological investigations of terpendole E analogues Org. Lett. 12 2010 2096 2099
149. F. Shidaifat, H. Canatan, S.K. Kulp, Y. Sugimoto, Y. Zhang, R.W. Brueggemeier, W.J. Somers, W.Y. Chang, H.C. Wang, and Y.C. Lin Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle Anticancer Res. 17 1997 1003 1009
150. M. Ligueros, D. Jeoung, B. Tang, D. Hochhauser, M.M. Reidenberg, and M. Sonenberg Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells Br. J. Cancer 76 1997 21 28
151. G. Liu, W.K. Kelly, G. Wilding, L. Leopold, K. Brill, and B. Somer An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer Clin. Cancer Res. 15 2009 3172 3176
152. N. Ready, N.A. Karaseva, S.V. Orlov, A.V. Luft, O. Popovych, J.T. Holmlund, B.A. Wood, and L. Leopold Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer J. Thorac. Oncol. 6 2011 781 785
153. R.S. Heist, J. Fain, B. Chinnasami, W. Khan, J.R. Molina, L.V. Sequist, J.S. Temel, P. Fidias, V. Brainerd, L. Leopold, and T.J. Lynch Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer Thorac. Oncol. 6 2010 1637 1643
154. L. Moretti, B. Li, K.W. Kim, H. Chen, and B. Lu AT-101, a Pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer J. Thorac. Oncol. 6 2010 680 687
155. M.Q. Baggstrom, Y. Qi, M. Koczywas, A. Argiris, E.A. Johnson, M.J. Millward, S.C. Murphy, C. Erlichman, C.M. Rudin, and R. Govindan A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer J. Thorac. Oncol. 6 2011 1757 1760
156. S. Liu, S.K. Kulp, Y. Sugimoto, J. Jiang, H.L. Chang, M.K. Dowd, P. Wan, and Y.C. Lin The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer Anticancer Res. 22 2001 33 38
157. R.C. Adlakha, C.L. Ashorn, D. Chan, and L.A. Zwelling Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II mediated DNA cleavage by gossypol Cancer Res. 49 1989 2052 2058
158. R. Baumgrass, M. Weiwad, F. Erdmann, J.O. Liu, D. Wunderlich, S. Grabley, and G. Fisher Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol J. Biol. Chem. 276 2001 47914 47921
159. A.S. Azmi, and R.M. Mohammad Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy J. Cell. Physiol. 218 2009 13 21
160. Y. Funayama, K. Nishio, K. Wakabayashi, M. Nagao, K. Shimoi, T. Ohira, S. Hasegawa, and N. Saijo Effects of β- and γ-carboline derivatives of DNA topoisomerase activities Mutat. Res. 349 1996 183 191
161. R. Cao, W. Peng, H. Chen, Y. Ma, X. Liu, X. Hou, H. Guan, and A. Xu DNA binding properties of 9-substituted harmine derivatives Biochem. Biophys. Res. Commun. 338 2005 1557 1563
162. R. Sakowicz, M.S. Berdelis, K. Ray, C.L. Blackburn, C. Hopmann, D.J. Faulkner, and L.S.B. Goldstein A marine natural product inhibitor of kinesin motors Science 280 1998 292 295
163. S. Brier, E. Carletti, S. DeBonis, E. Hewat, D. Lemaire, and F. Kozielski The marine natural product adociasulfate-2 as a tool to identify the MT-binding region of kinesins Biochemistry 45 2006 15644 15653
164. K.G. Reddie, D.R. Roberts, and T.M. Dore Inhibition of kinesin motor proteins by adociasulfate-2 J. Med. Chem. 49 2006 4857 4860
165. C. Jiang, Y. Chen, X. Wang, and Q. You Docking studies on kinesin spindle protein inhibitors: an important cooperative 'minor binding pocket' which increases the binding affinity significantly J. Mol. Model. 13 2007 987 992
166. K. Oguievetskaia, L. Martin-Chanas, A. Vorotyntsev, O. Doppelt-Azeroual, X. Brotel, S.A. Adcock, A.G. de Brevern, F. Delfaud, and F. Moriaud Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site J. Comput. Aided Mol. Des. 23 2009 571 582
167. X. Luo, M. Shu, Y. Wang, J. Liu, W. Yang, and Z. Lin 3D-QSAR studies of dihydropyrazole and dihydropyrrole derivatives as inhibitors of human mitotic kinesin Eg5 based on molecular docking Molecules 17 2012 2015 2029